Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Jakafi is a prescription kinase inhibitor containing ruxolitinib. Current labeling includes intermediate or high-risk myelofibrosis, polycythemia vera after inadequate response or intolerance to hydroxyurea, steroid-refractory acute graft-versus-host disease, and chronic graft-versus-host disease after failure of one or two systemic treatment lines.
read more about jakafi ...Ruxolitinib inhibits Janus-associated kinases JAK1 and JAK2. These kinases transmit signals from cytokines and growth factors involved in blood-cell production and immune function. Inhibition reduces abnormal or excessive JAK-STAT signaling.
Jakafi is used in adults with myelofibrosis or polycythemia vera under labeled criteria. It also treats steroid-refractory acute graft-versus-host disease and chronic graft-versus-host disease after prior systemic therapy in adults and pediatric patients age 12 and older.
Myelofibrosis starting doses range from 5 mg to 20 mg twice daily according to platelet count. Polycythemia vera starts at 10 mg twice daily. Acute graft-versus-host disease starts at 5 mg twice daily, while chronic graft-versus-host disease starts at 10 mg twice daily. Kidney function, liver function, blood counts, and interacting medicines can require dose changes.
Jakafi can cause thrombocytopenia, anemia, neutropenia, and serious bacterial, mycobacterial, fungal, or viral infections. Other concerns include symptom worsening after abrupt interruption, non-melanoma skin cancer, lipid elevations, major cardiovascular events, thrombosis, and secondary malignancies. Complete blood counts are monitored during treatment.
Jakafi treats selected myelofibrosis, polycythemia vera, acute graft-versus-host disease, and chronic graft-versus-host disease.
The starting dose is based on platelet count and ranges from 5 mg to 20 mg twice daily under current labeling.
The recommended starting dose is 10 mg twice daily.
Jakafi can lower platelets, red blood cells, and neutrophils, so complete blood counts are checked during therapy.
Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial. https://pubmed.ncbi.nlm.nih.gov/23423753/. Date Accessed October 5, 2026.
JAKAFI (Ruxolitinib) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f1c82580-87ae-11e0-bc84-0002a5d5c51b. Date Accessed October 5, 2026.
JAKAFI/JAKAFI XR (Ruxolitinib) Resources. https://www.incytemi.com/products/hematology/jakafi. Date Accessed October 5, 2026.
Ruxolitinib: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a612006.html. Date Accessed October 5, 2026.
Ruxolitinib Versus Standard Therapy for the Treatment of Polycythemia Vera. https://pubmed.ncbi.nlm.nih.gov/25629741/. Date Accessed October 5, 2026.